Allogene Therapeutics, Inc. (ALLO) FinancialsALLOFinancialAllogene Therapeutics, Inc.

Evaluating the bottom line, Allogene Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1011.21%, while the net margin is -919.76%. These profitability ratios, combined with a Return on Equity (ROE) of -42.39%, provide a clear picture of how effectively ALLO converts its operational activities into shareholder value.

In the context of the broader market, ALLO competes directly with industry leaders such as BBOT and STTK. With a market capitalization of $708.26M, it holds a significant position in the sector. When comparing efficiency, ALLO's gross margin of 100.00% stands against BBOT's N/A and STTK's N/A. Such benchmarking helps identify whether Allogene Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company reported a gross margin of 100% in Q2 2026, indicating potential for profitability once revenues stabilize. However, it has consistently reported net losses, with a net income loss of $42.68 million in the latest quarter.